Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
Status:
Terminated
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II trial to characterize the clinical outcome of standard of
care, cetuximab concurrent with radiation, in a special population (head and neck cancer
patients who cannot tolerate concurrent chemoradiotherapy due to advanced age, poor
performance status or concurrent illness), and to determine if biomarker response to a
loading dose of cetuximab is predictive of that outcome.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center